Reviva Pharmaceuticals (RVPH) investor relations material

Executive summary

• Focused on late-stage development of brilaroxazine for schizophrenia, with plans to initiate the RECOVER-2 Phase 3 trial in Q2 2026 and patient enrollment in Q3 2026, following FDA feedback requiring an additional trial before NDA submission.

• Announced a strategy to extend brilaroxazine's patent life and exclusivity, including a provisional patent filing for a new form of the drug, potentially extending exclusivity to 2046.

• Completed a $10 million public equity offering in March 2026.

• Common stock delisted from Nasdaq due to non-compliance with minimum bid price; trading to continue on OTCQB Venture Market as of May 14, 2026.

Financial highlights

• Net loss for Q1 2026 was $3.2 million ($0.46 per share), a significant improvement from $6.4 million ($2.61 per share) in Q1 2025, primarily due to lower R&D and G&A expenses.

• Cash and cash equivalents increased to $22.2 million as of March 31, 2026, up from $14.4 million at year-end 2025, driven by equity offerings.

• Operating expenses decreased to $3.3 million in Q1 2026 from $6.5 million in Q1 2025.

• Working capital surplus stood at $17.4 million, with total stockholders' equity at $17.4 million as of March 31, 2026.

• No revenue generated; company remains pre-commercial.

Outlook and guidance

• Expenses expected to increase as clinical development of brilaroxazine advances, including RECOVER-2 Phase 3 trial and NDA preparation.

• FDA feedback on the new brilaroxazine form for RECOVER-2 and NDA submission expected mid-2026.

• Current cash expected to fund operations into early 2027, but additional capital will be required before then; substantial doubt exists about ability to continue as a going concern without further fundraising.

• Company intends to seek additional funding through equity, debt, or collaborations.

• Additional brilaroxazine publications and partnership pursuits anticipated in 2026.